Report : Europe Travel Vaccines Market Forecast to 2028 – COVID-19 Impact and Analysis – by Product (Hepatitis A, Hepatitis B, Meningococcal Vaccines, and Others) and Application (Domestic Travel and Outbound Travel)
Others Segment to Dominate Europe Travel Vaccines Market during 2020–2028
According to a new market research study on “Europe Travel Vaccines Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product and Application” is expected to reach US$ 1,885.56 million by 2028 from 995.47 US$ million in 2021. The market is estimated to grow at a CAGR of 9.6% from 2021 to 2028. The report provides trends prevailing in the Europe travel vaccines market along with the drivers and restraints pertaining to the market growth. Rising incidences of infectious diseases is the major factor driving the growth of the Europe travel vaccines market. However, issues associated with travel vaccines being costly the growth of Europe travel vaccines market.
Europe travel vaccines market is segmented into product, application, and country. The Europe travel vaccines market, by product, is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. In 2021, the others segment held the largest share of the market. The Europe travel vaccines market, by application, is segmented into domestic travel and outbound travel. In 2021, the outbound travel segment held the largest share of the market. Based on country, the Europe travel vaccines market is segmented into France, Germany, Italy, UK, Russia, and the Rest of Europe.
Abbott; Dynavax Technologies; Emergent BioSolutions Inc.; GlaxoSmithKline plc; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Sanofi; and Valneva SE. are among the leading companies in the Europe travel vaccines market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, GlaxoSmithKline plc and Vir Biotechnology, Inc. had signed a binding agreement to expand their existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses.
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org